Novartis India Ltd — Dividend/Bonus, 10-05-2025: Corp. Action

Novartis India has announced a board meeting approving the financial results for the quarter and half-year ended March 31, 2025, reporting revenue from operations of ₹356.27 Cr and profit before tax of ₹130.42 Cr for the year. The Board has approved a final dividend of ₹25 per equity share, subject to shareholder approval. Mr. Sanker Parameswaran has been approved for re-appointment as a Non-Executive Independent Director for five years, pending shareholder consent. M K Saraf & Associates LLP has been appointed as Secretarial Auditors for five years, subject to shareholder approval. A postal ballot will be conducted for these approvals alongside the related party transaction with Novartis Pharma AG. The 77th Annual General Meeting and book closure dates have also been set. The statutory auditor issued an unmodified opinion on the audited results, indicating a clean audit.